Last reviewed · How we verify
VAC-3S
At a glance
| Generic name | VAC-3S |
|---|---|
| Sponsor | InnaVirVax |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1 (PHASE1, PHASE2)
- Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection (PHASE2)
- Phase I/IIa Dose-escalation Clinical Study of VAC-3S (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VAC-3S CI brief — competitive landscape report
- VAC-3S updates RSS · CI watch RSS
- InnaVirVax portfolio CI